Common stock and additional paid-in capital, shares authorized

  
AMGEN INC.CONSOLIDATED BALANCE SHEETSDecember 31, 2021 and 2020 (In millions, except per-share data)

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2021 |  | 2020 |
| ASSETS |
| Current assets: |  |  |  |
| Cash and cash equivalents | $ | 7,989  |  |  | $ | 6,266  |  |
| Marketable securities | 48  |  |  | 4,381  |  |
| Trade receivables, net | 4,895  |  |  | 4,525  |  |
| Inventories | 4,086  |  |  | 3,893  |  |
| Other current assets | 2,367  |  |  | 2,079  |  |
| Total current assets | 19,385  |  |  | 21,144  |  |
|  |  |  |  |
| Property, plant and equipment, net | 5,184  |  |  | 4,889  |  |
| Intangible assets, net | 15,182  |  |  | 16,587  |  |
| Goodwill | 14,890  |  |  | 14,689  |  |
| Other noncurrent assets | 6,524  |  |  | 5,639  |  |
| Total assets | $ | 61,165  |  |  | $ | 62,948  |  |
|  |  |  |  |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
| Current liabilities: |  |  |  |
| Accounts payable | $ | 1,366  |  |  | $ | 1,421  |  |
| Accrued liabilities | 10,731  |  |  | 10,141  |  |
| Current portion of long-term debt | 87  |  |  | 91  |  |
| Total current liabilities | 12,184  |  |  | 11,653  |  |
|  |  |  |  |
| Long-term debt | 33,222  |  |  | 32,895  |  |
|  |  |  |  |
| Long-term tax liabilities | 6,594  |  |  | 6,968  |  |
| Other noncurrent liabilities | 2,465  |  |  | 2,023  |  |
|  |  |  |  |
| Contingencies and commitments |  |  |  |
|  |  |  |  |
| Stockholders’ equity: |  |  |  |
| Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—558.3 shares in 2021 and 578.3 shares in 2020 | 32,096  |  |  | 31,802  |  |
| Accumulated deficit | (24,600) |  |  | (21,408) |  |
| Accumulated other comprehensive loss | (796) |  |  | (985) |  |
| Total stockholders’ equity | 6,700  |  |  | 9,409  |  |
| Total liabilities and stockholders’ equity | $ | 61,165  |  |  | $ | 62,948  |  |

See accompanying notes.F-6
